WHO ICTRP trial
Clinical and cost-effectiveness of an aripiprazole and sertraline drug…
ISRCTN63917405 · International Standard Randomised Controlled Trial Number (ISRCTN) · Recruiting
Key facts
| Trial ID | ISRCTN63917405 |
|---|---|
| Public title | Clinical and cost-effectiveness of an aripiprazole and sertraline drug combination in comparison with the drug quetiapine for the treatment of bipolar depression |
| Scientific title | Aripiprazole/sertraline combination: clinical and cost-effectiveness in comparison with quetiapine for the treatment of bipolar depression. An open label randomised controlled trial |
| Primary sponsor | Cumbria Northumberland Tyne and Wear NHS Foundation Trust |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase III |
| Countries | United Kingdom |
| Conditions | Bipolar depression Mental and Behavioural Disorders |
| Interventions | The ASCEnD trial is a prospective, two-arm, open-label, superiority, individually 1:1 randomised, controlled, pragmatic, parallel-group, type A open-label clinical trial. It aims to determine whether a sertraline/aripiprazole medication… |
| Registration date | Nov 23, 2023 |
| Target size | 270 |
| Secondary IDs | Nil known;Nil known;RES-20-32, IRAS 1007468, CPMS 57451 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: